tamoxifen + letrozole + anastrozole + exemestane

Tamoxifen + letrozole + anastrozole + exemestane refers to a group of standard-of-care hormonal therapies evaluated by the Institut Claudius Regaud in clinical research settings, specifically the MIRHO and PHACS trials. These studies investigate the use of these agents in patients with hormone-dependent breast cancer, focusing on identifying circulating microRNAs (miRNAs) as biomarkers for hormone sensitivity and exploring the correlations between pharmacokinetic and pharmacogenetic parameters. Tamoxifen acts as a competitive antagonist of the estrogen receptor, while letrozole, anastrozole, and exemestane function as aromatase inhibitors, reducing the production of estrogen in postmenopausal women. The research aims to personalize treatment and predict resistance in both adjuvant and metastatic settings.

Brand names

Aromasin

Other names

MIRHO protocolPHACS protocol